Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair M, Hofman P, Janssens A, van Kempen L, Kern I, Machado JC, Mohorčič K, Popat S, Ryška A, Wolf J, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: mohorcic k. Lancet Reg Health Eur. 2024 Mar 1;38:100839. doi: 10.1016/j.lanepe.2024.100839. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476751 Free PMC article. Review.
Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Dome B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W. Pirker C, et al. Among authors: mohorcic k. Clin Cancer Res. 2020 Jul 15;26(14):3819-3830. doi: 10.1158/1078-0432.CCR-19-3573. Epub 2020 Apr 21. Clin Cancer Res. 2020. PMID: 32317288
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.
Brcic L, Klikovits T, Megyesfalvi Z, Mosleh B, Sinn K, Hritcu R, Laszlo V, Cufer T, Rozman A, Kern I, Mohorcic K, Jakopovic M, Samarzija M, Seiwerth S, Kolek V, Fischer O, Jakubec P, Škarda J, Gieszer B, Hegedus B, Fillinger J, Renyi-Vamos F, Buder A, Bilecz A, Berger W, Grusch M, Hoetzenecker K, Klepetko W, Hoda MA, Filipits M, Dome B. Brcic L, et al. Among authors: mohorcic k. Transl Lung Cancer Res. 2021 Apr;10(4):1594-1607. doi: 10.21037/tlcr-20-1114. Transl Lung Cancer Res. 2021. PMID: 34012777 Free PMC article.
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Illini O, Hochmair MJ, Fabikan H, Weinlinger C, Tufman A, Swalduz A, Lamberg K, Hashemi SMS, Huemer F, Vikström A, Wermke M, Absenger G, Addeo A, Banerji S, Calles A, Clarke S, Di Maio M, Durand A, Duruisseaux M, Itchins M, Kääränien OS, Krenn F, Laack E, de Langen AJ, Mohorcic K, Pall G, Passaro A, Prager G, Rittmeyer A, Rothenstein J, Schumacher M, Wöll E, Valipour A. Illini O, et al. Among authors: mohorcic k. Ther Adv Med Oncol. 2021 Jun 11;13:17588359211019675. doi: 10.1177/17588359211019675. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34178121 Free PMC article.
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.
Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M, Dudnik E, Studnicka M, Öhman R, Wurm R, Wannesson L, Peled N, Kian W, Bar J, Daher S, Addeo A, Rotem O, Pall G, Zer A, Saad A, Cufer T, Sorotsky HG, Hashemi SMS, Mohorcic K, Stoff R, Rovitsky Y, Keren-Rosenberg S, Winder T, Weinlinger C, Valipour A, Hochmair MJ. Illini O, et al. Among authors: mohorcic k. Ther Adv Med Oncol. 2022 Jun 13;14:17588359221103206. doi: 10.1177/17588359221103206. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35720834 Free PMC article.
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair MJ, Hofman P, Janssens A, Johansson M, van Kempen L, Kern I, Lopez-Rios F, Lüchtenborg M, Machado JC, Mohorcic K, Paz-Ares L, Popat S, Ryška A, Taniere P, Wolf J, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: mohorcic k. Lancet Reg Health Eur. 2024 Mar 1;38:100838. doi: 10.1016/j.lanepe.2024.100838. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476742 Free PMC article. Review.
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, Demedts I, Dudnik E, Eisert A, Hashemi SMS, Janzic U, Kian W, Mohorcic K, Mohammed S, Silvoniemi M, Rothschild SI, Schulz C, Wesseler C, Addeo A, Armster K, Itchins M, Ivanović M, Kauffmann-Guerrero D, Koivunen J, Kuon J, Pavlakis N, Piet B, Sebastian M, Velthaus-Rusik JL, Wannesson L, Wiesweg M, Wurm R, Albers-Leischner C, Aust DE, Janning M, Fabikan H, Herold S, Klimova A, Loges S, Sharapova Y, Schütz M, Weinlinger C, Valipour A, Overbeck TR, Griesinger F, Jakopovic M, Hochmair MJ, Wermke M. Illini O, et al. Among authors: mohorcic k. Int J Mol Sci. 2024 Apr 3;25(7):3992. doi: 10.3390/ijms25073992. Int J Mol Sci. 2024. PMID: 38612799 Free PMC article.
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
Ljubicic L, Janzic U, Unk M, Terglav AS, Mohorcic K, Seiwerth F, Bitar L, Badovinac S, Plestina S, Korsic M, Kukulj S, Samarzija M, Jakopovic M. Ljubicic L, et al. Among authors: mohorcic k. Radiol Oncol. 2023 Sep 4;57(3):397-404. doi: 10.2478/raon-2023-0040. eCollection 2023 Sep 1. Radiol Oncol. 2023. PMID: 37665737 Free PMC article.
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G, Hoda MA, Klikovits T, Sinn K, Gschwandtner E, Mohorcic K, Schelch K, Pirker C, Peter-Vörösmarty B, Brankovic J, Dome B, Laszlo V, Cufer T, Rozman A, Klepetko W, Grasl-Kraupp B, Hegedus B, Berger W, Kern I, Grusch M. Vlacic G, et al. Among authors: mohorcic k. Cells. 2019 Sep 16;8(9):1091. doi: 10.3390/cells8091091. Cells. 2019. PMID: 31527449 Free PMC article.
15 results